[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ponv\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ponv":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,42,64,88,111,135,158,193,220,268,293,315,328],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100054055","effect-of-teas-on-ponv-after-spinal-surgery-100054055",false,"NCT03187535","Effect of TEAS on PONV After Spinal Surgery","The Effect of Transcutaneous Electric Acupoint Stimulation on Post-operative Nausea and Vomiting After Spinal Surgery","Inclusion Criteria:\n\n* Male and female patients , 18 or older\n* American Society of Anesthesiologists (ASA) classification I or II or III\n* Undergoing elective spinal surgery expected to last no more than four hours (from induction of anesthesia to extubation).\n* Capable and willing to consent\n\nExclusion Criteria:\n\n* Neuraxial (intrathecal or epidural) block\n* Significant ongoing history of vestibular disease or dizziness\n* Nausea or vomiting within 24 hours prior to surgery, use of antiemetic or emetogenic drugs within 3 days of surgery\n* Documented alcohol or substance abuse within 3 months before the surgery\n* Limb abnormalities such as burn and amputation.\n* Poorly controlled diabetes mellitus (fasting plasma glucose \\>126 mg\u002FdL or \\\u003C70 mg\u002FdL)\n* Implantation of metal\u002Felectrical devices, such as nerve stimulator, cardiac pacemaker, cardioverter, defibrillator and internal hearing aids\n* Rash, local infection, keloid, any dermatologic condition that could interfere with the acupoint stimulation area\n* Documented alcohol or substance abuse within 3 months before surgery\n* Presence of clinically diagnosed major psychiatric condition such as bipolar disorder, uncontrolled major depression, or schizophrenia\n* Chemotherapy or radiation therapy within 7 days before surgery\n* Investigational product use within 3 months prior surgery\n* Any condition, which in the opinion of the investigator would make subject ineligible for participation in the study (history of unstable cardiovascular, pulmonary, renal, hepatic, seizures)\n* Special population (prisoners, pregnant and lactating women)","ALL","18 Years",{"count":19,"type":20},72,"ESTIMATED","INTERVENTIONAL",[23],"NA","The proposed research will utilize electroacupuncture, a type of needleless acupuncture that uses electrostimulation, in a randomized, double blind study, to evaluate the incidence of post-operative nausea and vomiting (PONV) in patients undergoing spinal surgeries with the transcutaneous electrical acupoint stimulation (TEAS) compared to patients without TEAS.",[26],"PONV",[28],"Transcutaneous Electrical Acupoint Stimulation","RECRUITING","2026-07-09",{"date":32,"type":33},"2026-07-13","ACTUAL",{"date":35,"type":33},"2018-08-01",{"date":37,"type":20},"2027-12-20",{"name":39,"class":40},"Jyoti Pandya","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":21,"phases":52,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":41},"100642474","effect-of-lidocaine-through-gastric-tube-on-ponv-100642474","NCT07643298","Effect of Lidocaine Through Gastric Tube on PONV","Effect of Lidocaine Applied Via Nasogastric Tube on Postoperative Nausea and Vomiting in Obese Patients Undergoing Bariatric Surgery","Inclusion Criteria:\n\n* Adults aged between 18 and 65 years old;\n* American Society of Anesthesiologists (ASA) physical status classification II - III;\n* Planned to undergo primary elective laparoscopic sleeve gastrectomy with general anesthesia;\n* Capable of giving informed consent.\n\nExclusion Criteria:\n\n* Known allergy, hypersensitivity or contraindication to lidocaine or amide - type local anesthetics;\n* Previous significant liver or kidney dysfunction (e.g., ALT\u002FAST \\> 3 times the upper limit of normal, GFR \\\u003C 30 mL\u002Fmin);\n* History of epilepsy, cardiac conduction abnormalities or previous diagnosis of malignant hyperthermia;\n* Pregnancy or lactation;\n* Patients who received systemic lidocaine treatment during the operation;\n* History of severe postoperative nausea and vomiting (PONV) or motion sickness, requiring multiple prophylactic medications;\n* Emergency or revision bariatric surgery.","65 Years",{"count":51,"type":20},100,[23],"The goal of this clinical trial is to learn if intragastric administration of lidocaine can reduce postoperative nausea and vomiting in obese patients undergoing laparoscopic sleeve gastrectomy. The main question it aims to answer is:\n\nDoes administering 0.5% lidocaine via an orogastric tube reduce the incidence of postoperative nausea and vomiting (PONV) in the post-anesthesia care unit and within the first 24 hours after surgery compared to a placebo (normal saline)?\n\nResearchers will compare the Lidocaine Group to the Placebo Group to see if the intervention lowers the PONV incidence.\n\nParticipants will:\n\n* Receive the assigned study solution (either 0.5% lidocaine 20ml or normal saline 20ml) through an orogastric tube upon surgery completion and before extubation.\n* Have their gastric tube clamped for 5 minutes to ensure mucosal exposure before removal.\n* Undergo standardized total intravenous anesthesia and perioperative management according to the study protocol.\n* Be assessed for nausea, vomiting, and other outcomes at specified time points postoperatively in the recovery room and at 6, 12, and 24 hours.",[26],"2026-06-09",{"date":57,"type":33},"2026-06-11",{"date":59,"type":33},"2026-05-20",{"date":61,"type":20},"2027-06-30",{"name":63,"class":40},"General Hospital of Ningxia Medical University",{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":4,"eligibilityCriteria":70,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":71,"enrollmentInfo":72,"targetDuration":4,"studyType":21,"phases":74,"briefSummary":76,"conditions":77,"keywords":4,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":41},"100642649","phase-4-aprepitant-to-improve-same-day-discharge-for-tka-100642649","NCT07639723","Aprepitant to Improve Same Day Discharge for TKA","Preoperative Aprepitant to Improve Same-Day Discharge After Total Knee Arthroplasty: A Randomized Double-Blind Placebo-Controlled Trial","Inclusion Criteria:\n\n* Receiving primary, unilateral elective TKA with or without abductor canal block\n* Asa I-III\n* Age 18-90\n* Ability to receive ondansetron and dexamethasone\n* Ability to consent and complete surveys\n* English or Spanish speaking\n* Receiving regional anesthesia (epidural or spinal) for surgery\n\nExclusion Criteria:\n\n* Allergy to any of the anti-emetics being administered\n* Current treatment of pimozide\n* Emergent surgery\n* Revision\u002F multiple revisions of TKA\n* Clinical suspicion of possible bowel obstruction\n* Need for general anesthesia\n* Pregnant\u002Fbreast feeding\n* AST\\> 2.5 x the upper limit of normal or ALT\\> 2.5 x upper limit of normal, bilirubin\\> 1.5x upper limit of normal\n* Need for opioid or benzodiazepine antagonists\n* Not planned for same day discharge\n* Enrollment in a different drug trial for TKA\n* Unable to consent in English or Spanish","90 Years",{"count":73,"type":20},350,[75],"PHASE4","The purpose of this research is to study whether adding an FDA approved medication called aprepitant (a medication given to patients like you to reduce or eliminate nausea and vomiting) to the usual treatment to prevent nausea and vomiting given to patients during knee replacement surgery helps more patients go home on the same day of surgery (before midnight) by eliminating nausea and vomiting.",[26],"NOT_YET_RECRUITING","2026-06-06",{"date":81,"type":33},"2026-06-10",{"date":83,"type":20},"2026-07",{"date":85,"type":20},"2027-08",{"name":87,"class":40},"Endeavor Health",{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":4,"eligibilityCriteria":94,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":49,"enrollmentInfo":95,"targetDuration":4,"studyType":21,"phases":97,"briefSummary":98,"conditions":99,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":41},"100629805","oliceridine-versus-sufentanil-for-postoperative-nausea-in-cerebellopontine-angle-surgery-100629805","NCT07479446","Oliceridine Versus Sufentanil for Postoperative Nausea in Cerebellopontine Angle Surgery","Comparative Study of Oliceridine Versus Sufentanil for Patient-Controlled Intravenous Analgesia in Improving Postoperative Nausea in Patients Undergoing Cerebellopontine Angle Region Surgery.","Inclusion Criteria:\n\n* Scheduled for elective CPA region surgery with planned PCIA.\n* Age 18-65 years.\n* ASA physical status I-III.\n* Provides written informed consent.\n\nExclusion Criteria:\n\n* Opioid tolerance (taking opioids ≥1 week, equivalent to oral morphine ≥50 mg\u002Fday or oxycodone ≥30 mg\u002Fday).\n* Severe cardiopulmonary, hepatic, renal, vascular, neurological, hematological, gastrointestinal, or endocrine diseases.\n* Postoperative ICU admission with tracheal intubation.\n* BMI ≤18.5 or ≥30 kg\u002Fm².\n* Participation in another clinical trial within 3 months prior to screening.",{"count":96,"type":20},174,[23],"This single-center, double-blind, randomized controlled trial aims to determine whether oliceridine for patient-controlled intravenous analgesia (PCIA) can significantly reduce the incidence of postoperative nausea, an opioid-related adverse reaction, compared to sufentanil PCIA in patients undergoing cerebellopontine angle (CPA) region surgery. A secondary objective is to compare the postoperative analgesic effects between the two drugs. The study plans to enroll 174 patients (with a calculated sample size of 164 plus 5% for attrition). The primary outcome is the incidence of nausea within 6-48 hours postoperatively. Secondary outcomes include pain scores at rest and during movement within 48 hours, and other exploratory outcomes such as vomiting incidence, time to first flatus\u002Fdefecation, and gastrointestinal function scores.",[26,100,101,102],"Cerebellopontine Angle Tumor","Microvascular Decompression Surgery","Postoperative Analgesia",{"date":104,"type":33},"2026-05-22",{"date":106,"type":33},"2026-03-25",{"date":108,"type":20},"2027-09-30",{"name":110,"class":40},"Xuanwu Hospital, Beijing",{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":117,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":119,"minAge":17,"maxAge":120,"enrollmentInfo":121,"targetDuration":4,"studyType":123,"phases":4,"briefSummary":124,"conditions":125,"keywords":4,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":4},"100635542","amisulpride-for-the-prevention-of-postoperative-nausea-and-vomiting-in-patients-undergoing-laparoscopic-surgery-100635542","NCT07554040","Amisulpride for the Prevention of Postoperative Nausea and Vomiting in Patients Undergoing Laparoscopic Surgery","Amisulpride Used for the Prevention of Postoperative Nausea and Vomiting in Patients Undergoing Laparoscopic Surgery: a Prospective Observational Cohort Study","Amisulpride","Inclusion Criteria:\n\n* 1\\. 18\\\u003CBMI≤30kg\u002Fm2 2. Patients scheduled to undergo gynecological laparoscopic surgery (e.g., ovary, fallopian tube, uterus, and gynecological tumors, etc., with an expected surgery duration of ≤3 hours)\n\nExclusion Criteria:\n\n* 1\\. ASA class IV or above 2. Long-term use of opioid drugs or non-steroidal anti-inflammatory drugs 3. Undergoing radiotherapy and chemotherapy 4.Allergic to the medication used 5.Pregnant or breastfeeding women 6.Previously existing vestibular disorders or chronic dizziness, easily nauseous 7.Recent use of antiemetic drugs or prophylactic antiemetic regimen (within 7 days before surgery) 8.Presence of neurological or psychiatric disorders, or cognitive impairment","FEMALE","75 Years",{"count":122,"type":20},526,"OBSERVATIONAL","This study aims to focus on patients undergoing gynecological laparoscopic surgery and further evaluate the role of amisulpride in preventing postoperative nausea and vomiting in these patients.",[26],"2026-04-21",{"date":128,"type":33},"2026-04-28",{"date":130,"type":20},"2026-05-10",{"date":132,"type":20},"2026-12-10",{"name":134,"class":40},"Second Affiliated Hospital, School of Medicine, Zhejiang University",{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":4,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":142,"targetDuration":4,"studyType":21,"phases":144,"briefSummary":145,"conditions":146,"keywords":147,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":154,"leadSponsor":156,"locationsCount":41},"100632541","electroacupuncture-plus-5-ht3-receptor-inhibitor-for-ponv-prevention-in-high-risk-patients-undergoing-thoracoscopic-lung-cancer-surgery-100632541","NCT07515027","Electroacupuncture Plus 5-HT3 Receptor Inhibitor for PONV Prevention in High-Risk Patients Undergoing Thoracoscopic Lung Cancer Surgery","Electroacupuncture Combined With 5-HT3 Receptor Inhibitor for the Prevention of Postoperative Nausea and Vomiting in High-risk Patients Undergoing Thoracoscopic Surgery for Lung Cancer","Inclusion Criteria:\n\n* Age ≥ 18 years;\n* American Society of Anesthesiologists (ASA) physical status I-III;\n* Body mass index (BMI) 18-30 kg\u002Fm²;\n* Scheduled for elective video-assisted thoracoscopic surgery (VATS) lobectomy, segmentectomy, or wedge resection;\n* Expected to receive postoperative opioid analgesia, with an Apfel risk score ≥ 3;\n* Normal pulmonary function, without severe cardiovascular, hepatic, or renal abnormalities;\n* No infection around the acupuncture sites;\n* Voluntary written informed consent provided by the subject.\n\nExclusion Criteria:\n\n* Severe systemic diseases, such as cardiovascular, hepatic, or renal abnormalities, or poor pulmonary function;\n* Subjects with cognitive dysfunction or psychological disorders;\n* History of previous esophageal or gastric surgery;\n* Hypersensitivity to acupuncture or any study medications;\n* Severe infection or history of surgery around the acupuncture sites;\n* Pregnant or lactating women;\n* Long-term opioid use;\n* Conversion to open surgery;\n* Acupuncture treatment received within 1 month prior to enrollment.",{"count":143,"type":20},204,[23],"This prospective, randomized controlled study aims to evaluate the efficacy and safety of electroacupuncture combined with 5-HT3 receptor inhibitor for preventing postoperative nausea and vomiting (PONV) in high-risk patients undergoing thoracoscopic lung cancer surgery. The primary outcome is the incidence of PONV within 24 hours after surgery.",[26],[26,148,149],"EA","VATS","2026-04-07",{"date":152,"type":33},"2026-04-13",{"date":150,"type":20},{"date":155,"type":20},"2026-12-31",{"name":157,"class":40},"Shanghai Chest Hospital",{"id":159,"slug":160,"hasResults":11,"nctId":161,"briefTitle":162,"officialTitle":163,"acronym":4,"eligibilityCriteria":164,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":165,"enrollmentInfo":166,"targetDuration":4,"studyType":21,"phases":168,"briefSummary":169,"conditions":170,"keywords":175,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":192},"100620427","comparison-of-target-controlled-and-manual-total-intravenous-anesthesia-in-supratentorial-surgery-100620427","NCT07357480","Comparison of Target-Controlled and Manual Total Intravenous Anesthesia in Supratentorial Surgery","Comparison of Target-Controlled Infusion Using the Eleveld Model and Manual Total Intravenous Anesthesia on Intraoperative Anesthetic Consumption and Postoperative Pain and Delirium in Supratentorial Surgery","Inclusion Criteria:\n\n* Adult patients aged 18 to 60 years\n* Scheduled for elective supratentorial surgery under general anesthesia\n* American Society of Anesthesiologists (ASA) physical status I or II\n* Planned total intravenous anesthesia with propofol and remifentanil\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Refusal or inability to provide written informed consent\n* American Society of Anesthesiologists (ASA) physical status III or higher\n* Pregnancy\n* Emergency surgery\n* Presence of brain herniation\n* Anticipated or documented difficult airway\n* Inability to communicate effectively (e.g., non-Turkish speaking or hearing impairment)\n* Preoperative risk factors for delirium, including substance abuse, use of neuropsychiatric medications, preoperative hemoglobin level \\\u003C 8 g\u002FdL, malnutrition, or electrolyte or thyroid hormone abnormalities\n* Intraoperative deviation from the study protocol, including changes in surgical or anesthetic technique or occurrence of major intraoperative complications\n* Contraindications to propofol or remifentanil","60 Years",{"count":167,"type":20},70,[23],"This study aims to investigate the effect of target-controlled infusion using the Eleveld pharmacokinetic model compared with manually controlled total intravenous anesthesia on the incidence of postoperative delirium in patients undergoing supratentorial surgery. Propofol and remifentanil are administered using either target-controlled or manual infusion techniques according to the study protocol. Secondary objectives include comparisons of intraoperative anesthetic consumption, hemodynamic responses, recovery profiles, postoperative pain, and postoperative nausea and vomiting between the two anesthesia strategies. The study seeks to evaluate whether target-controlled infusion provides improved anesthetic management and postoperative outcomes compared with manual total intravenous anesthesia.",[171,172,26,173,174],"Postoperative Delirium (POD)","Postoperative Pain","Burst Suppression","Recovery Period, Anesthesia",[176,177,178,179,180,181,182,183],"Target Controlled Infusion","Total Intravenous Anesthesia","Eleveld Model","Postoperative Delirium","Supratentorial Surgery","Bispectral Index","Propofol","Remifentanil","2026-03-24",{"date":106,"type":33},{"date":187,"type":33},"2026-01-14",{"date":189,"type":20},"2026-05",{"name":191,"class":40},"Istanbul University - Cerrahpasa",2,{"id":194,"slug":195,"hasResults":11,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":4,"eligibilityCriteria":199,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":49,"enrollmentInfo":200,"targetDuration":4,"studyType":21,"phases":202,"briefSummary":203,"conditions":204,"keywords":206,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":41},"100629029","comparison-of-the-effects-of-moderate--and-high-dose-glucocorticoids-on-postoperative-recovery-100629029","NCT07469332","Comparison of the Effects of Moderate- and High-Dose Glucocorticoids on Postoperative Recovery","Comparison of the Effects of Moderate- and High-Dose Glucocorticoid Administration on Postoperative Recovery: A Prospective Randomized Controlled Trial","Inclusion Criteria:\n\n* Age between 18 and 65 years\n* ASA physical status I-II\n* Scheduled for elective laparoscopic cholecystectomy\n* Undergoing general anesthesia\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Patients younger than 18 years or older than 65 years\n* Known allergy to dexamethasone\n* ASA physical status III or higher\n* Surgical procedures lasting longer than 120 minutes\n* Emergency surgeries\n* Pregnant or breastfeeding patients\n* Patients with coagulopathy or receiving anticoagulant therapy\n* Known allergy to local anesthetics\n* Localized infection at the injection site\n* Inflammatory bowel disease\n* Autoimmune diseses\n* Chronic pain conditions\n* Ocular herpes simplex infection\n* Cushing's disease\n* Myasthenia gravis\n* Anticipated poor compliance with the study protocol\n* Vaccination within the last 14 days\n* Use of systemic glucocorticoids or immunosuppressive drugs\n* İmpaired renal function (GFR \\\u003C 30 mL\u002Fmin)\n* Liver cirrhosis\n* Congestive heart failure\n* Peripheral nerve disorders\n* Elective laparoscopic cholecystectomy due to malignancy\n* Conversion to open surgery during the operation\n* Epilepsy\n* Body mass index (BMI) \\> 30 kg\u002Fm²",{"count":201,"type":20},135,[23],"Laparoscopic cholecystectomy is a commonly performed minimally invasive surgical procedure; however, postoperative pain, nausea, and delayed recovery remain clinically relevant problems. Glucocorticoids such as dexamethasone are widely used in perioperative care for the prevention of postoperative nausea and vomiting and as part of multimodal analgesia strategies.\n\nThis prospective randomized controlled trial aims to compare the effects of moderate- and high-dose intravenous dexamethasone administered intraoperatively on postoperative recovery in patients undergoing elective laparoscopic cholecystectomy. The primary outcomes include postoperative nausea and vomiting, inflammatory markers (CRP and WBC), and Quality of Recovery-15 (QoR-15) scores. Secondary outcomes include postoperative pain scores, intraoperative remifentanil consumption, postoperative opioid consumption, and adverse events.",[205,26],"Postoperative Recovery",[205,172,207,208,209,210],"dexamethasone","Postoperative Nausea and Vomiting","high dose","moderate dose","2026-03-09",{"date":213,"type":33},"2026-03-13",{"date":215,"type":20},"2026-03-30",{"date":217,"type":20},"2026-07-30",{"name":219,"class":40},"Ankara City Hospital Bilkent",{"id":221,"slug":222,"hasResults":11,"nctId":223,"briefTitle":224,"officialTitle":225,"acronym":4,"eligibilityCriteria":226,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":227,"enrollmentInfo":228,"targetDuration":4,"studyType":21,"phases":230,"briefSummary":231,"conditions":232,"keywords":239,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":259,"lastUpdatePostDateStruct":260,"startDateStruct":262,"completionDateStruct":264,"leadSponsor":266,"locationsCount":41},"100599458","non-opioid-anesthesia-based-on-thoracic-paravertebral-block-during-laparoscopic-sleeve-gastrectomy-100599458","NCT07084753","Non-opioid Anesthesia Based on Thoracic Paravertebral Block During Laparoscopic Sleeve Gastrectomy","Comparison of Opioid-based Anesthesia, Opioid-free Anesthesia Based on Intravenous Drugs and Opioid-free Anesthesia With Thoracic Paravertebral Block, in Patients Undergoing Laparoscopic Gastric Bypass Surgery for Obesity","Inclusion Criteria:\n\n-. patients with a prior history of treatment by a multidisciplinary obesity team scheduled for laparoscopic sleeve gastrectomy (LSG)\n\n* body mass index of 30 kg\u002Fm² or greater\n* patients classified as ASA status 2-3.\n\nExclusion Criteria:\n\n* allergies to the intended medications\n* patient refusal\n* uncontrolled psychiatric disorders\n* intracranial pathology\n* cerebrovascular damage\n* any factors impairing effective communication\n\nAdditional Exclusion Criteria:\n\n1. For patients receiving thoracic paravertebral block (TPVB):\n\n   \\- the presence of infection at the puncture site\n2. For the OFA group:\n\n   * 2nd or 3rd-degree atrioventricular block\n   * bradycardia with a heart rate below 50 beats per minute\n   * coronary artery disease,\n   * cardiomyopathy.","70 Years",{"count":229,"type":20},36,[23],"Regional anesthesia is a technique in which a local anesthetic is injected near a nerve or spinal cord to block sensation, motor stimulation, and pain. In this study, an ultrasound-guided paravertebral block will be used, with careful consideration of all positive and negative factors and possible complications. A thoracic paravertebral block is performed by inserting a needle into the intercostal spaces on the back, approximately 4 cm lateral to the spine. Many studies support excellent pain control with this technique, during and after surgery in thoracic and abdominal surgery. Investigators aim to achieve faster patient mobility after surgery, rapid recovery of bowel function, reduced nausea and vomiting, and maximum pain control. The use of opioids, which can additionally cause respiratory suppression and drowsiness, is avoided.\n\nAt any time in case of need to switch from laparoscopic to open surgery, equally adequate anesthesia and postoperative analgesia are ensured without the need to change the approach to the same. In this study, the basic scientific assumption (hypothesis) of the researchers is that non-opioid anesthesia with thoracic paravertebral block provides adequate pain control during and long-term after the surgical procedure, without the side effects of opioid anesthesia.\n\nThe main goal of the study is to determine which type of anesthesia results in the best pain control and most significantly reduces complications of anesthesia and surgery in overweight patients who are scheduled for laparoscopic longitudinal gastrectomy and partial\u002Ftotal gastrectomy.",[233,234,235,236,26,102,172,237,238],"Obese Patients","Bariatric Surgical Pain","Bariatric Surgery (Sleeve Gastrectomy )","Non-Opioid Pain Management","Thoracic Paravertebral Block","Opioid Free Anesthesia",[240,241,242,243,244,245,246,247,248,249,250,251,252,253,254,174,236,26,255,256,257,258],"thoracic paravertebral block","obese patients","bariatric surgery","sleeve gastrectomy","postoperative pain management","anesthesia recovery period","non-opioid anesthesia","recovery after bariatric surgery","TPVB","OFA based on thoracic paravertebral block","Visceral pain, Postoperative","Opioid based anesthesia","Opioid free anesthesia","OBA","OFA","Postoperative analgesia","Postoperative pain","Bariatric Surgery, Pain","Opioid free anesthesia, dexmedetomidine, ketamine, lidocaine","2025-07-17",{"date":261,"type":33},"2025-07-24",{"date":263,"type":20},"2025-07-30",{"date":265,"type":20},"2025-10",{"name":267,"class":40},"IVO JURISIC",{"id":269,"slug":270,"hasResults":11,"nctId":271,"briefTitle":272,"officialTitle":273,"acronym":4,"eligibilityCriteria":274,"healthyVolunteers":11,"sex":119,"minAge":275,"maxAge":49,"enrollmentInfo":276,"targetDuration":4,"studyType":21,"phases":278,"briefSummary":279,"conditions":280,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":284,"lastUpdatePostDateStruct":285,"startDateStruct":287,"completionDateStruct":289,"leadSponsor":291,"locationsCount":41},"100596871","dual-chamber-patient-controlled-analgesia-for-postoperative-recovery-100596871","NCT07051109","Dual-chamber Patient-controlled Analgesia for Postoperative Recovery","Comparison of Postoperative Recovery Between Dual-channel Pump for Intravenous Patient-controlled Analgesia(IV-PCA) and Conventional Single-channel Pump After Laparoscopic Sleeve Gastrectomy: a Prospective Randomized Controlled Trial","Inclusion Criteria:\n\n* Adult females aged 19 to 65 years\n* American Society of Anesthesiologists physical status (ASA class) 1 to 3\n* Patients scheduled for laparoscopic sleeve gastrectomy under general anesthesia\n* Patients requesting the use of IV-PCA after surgery\n\nExclusion Criteria:\n\n* Patients with hypersensitivity to the drugs used in this study (Ketorolac, Fentanyl)\n* Patients with alcohol or drug dependence, long-term use of opioids or analgesics\n* Patients with liver disease or renal failure\n* Patients with peptic ulcer, patients with gastrointestinal bleeding predisposition\n* Patients with suspected cerebrovascular hemorrhage, organic disorders of the head related to increased intracranial pressure\n* Patients with bronchial asthma or bronchospasm symptoms\n* Patients with severe respiratory depression\n* Nasal polyps, angioedema\n* Patients with or history of convulsive disease\n* Patients for whom the use of neuromuscular blocking agents is contraindicated","19 Years",{"count":277,"type":20},92,[23],"Postoperative nausea and vomiting (PONV) are the most common complications that can occur after general anesthesia. Postoperative use of opioids and morbid obesity have been reported as risk factors of PONV. In this study, the investigators aimed to compare the degree of postoperative side effects and pain control when an intravenous patient-controlled analgesia combining fentanyl and ketorolac via a dual-chamber device was provided to participants undergoing laparoscopic sleeve gastrectomy.",[281,282,283,26],"Morbid Obesity","PCA","Analgesia","2025-06-25",{"date":286,"type":33},"2025-07-03",{"date":288,"type":33},"2022-10-11",{"date":290,"type":20},"2026-03-11",{"name":292,"class":40},"Seoul National University Bundang Hospital",{"id":294,"slug":295,"hasResults":11,"nctId":296,"briefTitle":297,"officialTitle":297,"acronym":4,"eligibilityCriteria":298,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":299,"targetDuration":4,"studyType":123,"phases":4,"briefSummary":300,"conditions":301,"keywords":302,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":306,"lastUpdatePostDateStruct":307,"startDateStruct":309,"completionDateStruct":311,"leadSponsor":313,"locationsCount":4},"100585379","sugammadex-reduces-antiemetic-effect-of-dexamethasone-100585379","NCT06901596","Sugammadex Reduces Antiemetic Effect of Dexamethasone","Inclusion Criteria:\n\n* Older than 18 years old\n* Elective surgery\n* ASA 1, 2, 3\n* At least one risk factor for PONV\n\nExclusion Criteria:\n\n* Pregnancy\n* Receiving antiemetics prior to arrival to preoperative holding area\n* Receiving opioids prior to arrival to preoperative holding area\n* Admission to ICU\n* Altered mental status\n* Rapid sequence induction\n* Nausea or vomiting before surgery",{"count":51,"type":20},"Sugammadex is a medication used for reversal of muscle relaxation during procedures under general anesthesia. It works by encapsulating muscle relaxant molecules with a steroid ring in its structure. On the other hand, postoporative nause and vomiting (PONV) is an adverse outcome during anesthesia. PONV can be prevented with pharmacologic agents such as ondansetron and dexamethasone. Dexamethasone is a steroidal agent that can interact with sugammadex. In theory, this interaction could lead to reduced effectiveness of sugammadex. In fact, several studies have explored this interaction. However, the effect of sugammadex on the antiemetic effect of dexamethasone has not been evaluated. This study intends to evaluate this interaction.",[26],[303,207,26,304,305],"sugammadex","perioperative","surgery","2025-03-23",{"date":308,"type":33},"2025-03-30",{"date":310,"type":20},"2025-04-01",{"date":312,"type":20},"2025-07-15",{"name":314,"class":40},"Augusta University",{"id":316,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":317,"targetDuration":4,"studyType":21,"phases":318,"briefSummary":24,"conditions":319,"keywords":320,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":321,"lastUpdatePostDateStruct":322,"startDateStruct":324,"completionDateStruct":325,"leadSponsor":327,"locationsCount":41},"100300167",{"count":19,"type":20},[23],[26],[28],"2025-03-19",{"date":323,"type":33},"2025-03-24",{"date":35,"type":33},{"date":326,"type":20},"2026-12-20",{"name":39,"class":40},{"id":329,"slug":330,"hasResults":11,"nctId":331,"briefTitle":332,"officialTitle":333,"acronym":4,"eligibilityCriteria":334,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":335,"targetDuration":337,"studyType":123,"phases":4,"briefSummary":338,"conditions":339,"keywords":342,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":344,"lastUpdatePostDateStruct":345,"startDateStruct":347,"completionDateStruct":349,"leadSponsor":351,"locationsCount":41},"100522510","pain-and-nausea-after-gallbladder-surgery-100522510","NCT06083558","Pain and Nausea After Gallbladder Surgery","Pain and Nausea in the Post-anesthesia Care Unit Following Gallbladder Surgery - a Registry Study Using National Data From Gallriks and the Swedish Perioperative Register (SPOR)","Inclusion Criteria:\n\n* Primary gallstone surgery\n* Adult patients (\\>=18 years)\n* Procedure performed between 2016 and 2025\n* Surgical procedure registered in the national quality registry Gallriks.\n\nExclusion Criteria:\n\n* If multiple surgeries on the same patient in the study database, subsequent procedures to the first procedure is excluded.",{"count":336,"type":20},50000,"6 Months","The study is primarily an exploratory study of quality registry data for a swedish national cohort of patients who have undergone gallbladder surgery or ERCP, with the aim of investigating the occurrence of pain and PONV (Postoperative Nausea and Vomiting) after gallbladder surgery. Furthermore, the investigators will explorer if there are factors related to the patient or the surgical procedure that are associated with a higher risk of PONV or pain.",[26,172,340,341],"Postoperative Complications","Gall Bladder Disease",[343],"cholecystectomy","2023-10-11",{"date":346,"type":33},"2023-10-16",{"date":348,"type":33},"2016-01-01",{"date":350,"type":20},"2028-03",{"name":352,"class":40},"Umeå University"]